CTNM FY 2025 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$323,000

Operating Income

-$68M

Net Income

-$60M

EPS (Diluted)

$-2.17

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$56M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$277M

Total Liabilities

$16M

Stockholders' Equity

$261M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$323,000	-$258,000	-25.2%
Operating Income	-$68M	-$51M	-33.7%
Net Income	-$60M	-$42M	-41.9%